NEW YORK (GenomeWeb) – Epic Sciences today announced the expansion of its existing credit facility with Silicon Valley Bank to $15 million.
Epic Sciences previously had access to $5 million under the facility. The San Diego-based firm also said that the maturity of the facility has been extended by 27 months to April 1, 2019.
The new terms provide the company with the ability to accelerate the expansion of its research capabilities and product development work, it said.
Epic Sciences is developing diagnostic tests for the rapid quantification of proteomic and genomic changes that occur during the course of a patient's cancer. Its No Cell Left Behind platform can detect all categories of circulating tumor cells in blood and is compatible with single-cell genomic and proteomic analysis.